These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 25454364)

  • 1. [Place of the opioid system in biology and treatment of Alcohol Use Disorder].
    Nubukpo P
    Encephale; 2014 Dec; 40(6):457-67. PubMed ID: 25454364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent developments in alcoholism:opioid peptides.
    Froehlich JC; Li TK
    Recent Dev Alcohol; 1993; 11():187-205. PubMed ID: 7901877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Benefits in reducing alcohol consumption: how nalmefene can help].
    Bendimerad P; Blecha L
    Encephale; 2014 Dec; 40(6):495-500. PubMed ID: 25454365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Alcohol dependence and opioid receptor -Pharmacological profile of nalmefene].
    Ohgi Y
    Nihon Yakurigaku Zasshi; 2020; 155(3):145-148. PubMed ID: 32378631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of alcohol dependence: recent progress and reduction of consumption.
    Testino G; Leone S; Borro P
    Minerva Med; 2014 Dec; 105(6):447-66. PubMed ID: 25392958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endogenous opioid systems and alcohol addiction.
    Herz A
    Psychopharmacology (Berl); 1997 Jan; 129(2):99-111. PubMed ID: 9040115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioid Receptor Antagonists in the Treatment of Alcoholism.
    Serecigni JG
    Adicciones; 2015 Sep; 27(3):214-30. PubMed ID: 26437315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacological profile and clinical findings of nalmefene (Selincro
    Tadori Y
    Nihon Yakurigaku Zasshi; 2020; 155(2):113-119. PubMed ID: 32115477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Nalmefene and Opioid Withdrawal Syndrome: Analysis of the Global Pharmacovigilance Database for Adverse Drug Reactions].
    Dahmke H; Kupferschmidt H; Kullak-Ublick GA; Weiler S
    Praxis (Bern 1994); 2015 Oct; 104(21):1129-34. PubMed ID: 26463904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nalmefene for the treatment of alcohol dependence: a current update.
    Soyka M
    Int J Neuropsychopharmacol; 2014 Apr; 17(4):675-84. PubMed ID: 24246244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacological effects of a mu-opioid receptor antagonist naltrexone on alcohol dependence].
    Kato H
    Nihon Arukoru Yakubutsu Igakkai Zasshi; 2008 Oct; 43(5):697-704. PubMed ID: 19068776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of the endogenous opioid system on high alcohol consumption and genetic predisposition to alcoholism.
    Gianoulakis C
    J Psychiatry Neurosci; 2001 Sep; 26(4):304-18. PubMed ID: 11590970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions.
    Kreek MJ; Schluger J; Borg L; Gunduz M; Ho A
    J Pharmacol Exp Ther; 1999 Jan; 288(1):260-9. PubMed ID: 9862779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of alcoholism as a chronic disorder.
    O'Brien CP
    EXS; 1994; 71():349-59. PubMed ID: 8032166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The opioidergic-alcohol link : implications for treatment.
    Modesto-Lowe V; Fritz EM
    CNS Drugs; 2005; 19(8):693-707. PubMed ID: 16097851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Alcohol use disorders: current approaches to diagnosis and treatment].
    Sivolap YP
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(9):23-27. PubMed ID: 26525810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions between cannabinoid and opioid receptor systems in the mediation of ethanol effects.
    Manzanares J; Ortiz S; Oliva JM; Pérez-Rial S; Palomo T
    Alcohol Alcohol; 2005; 40(1):25-34. PubMed ID: 15550451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential.
    Soyka M
    Expert Opin Pharmacother; 2016; 17(4):619-26. PubMed ID: 26810044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nalmefene. Alcohol dependence: no advance.
    Prescrire Int; 2014 Jun; 23(150):150-2. PubMed ID: 25121147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of cocaine craving with as-needed nalmefene, a partial κ opioid receptor agonist: first clinical experience.
    Grosshans M; Mutschler J; Kiefer F
    Int Clin Psychopharmacol; 2015 Jul; 30(4):237-8. PubMed ID: 25647453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.